Apollon Formularies Plc Share Price (APOL.PL)

With these shares selling at 0.02 today (80% down from 3 months ago) and delisting imminent with no offered trading platform, why have some shareholders/evangelists not yet written off their investment?

If Global Hemp buy any assets, the remnants will be worthless and any cash will disappear so shareholders will get nothing.

If it looks like a scam and smells like a scam it probably is a scam.

“Jamaica boasts 52% of the world’s medicinal plants, and we’re exploring new botanical medicines to bring health, wellness, and economic growth to our nation,” she said.

https://www.msn.com/en-us/news/us/dea-sanctioned-jamaica-sends-first-ever-legal-cannabis-products-to-us-for-analytical-testing/ar-BB1iSm1S

Https://www.youtube.com/watch?v=seL74WmFDSE

About Global Hemp Group Inc.

Global Hemp Group Inc. (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) is a dynamic company currently focused on two key business segments - Industrial Hemp and Biopharma.

The Industrial Hemp division’s primary focus lies in the environmental uses of hemp for construction and hemp for sustainable bio-energy sources, both contributing to a carbon-negative footprint. Our R&D team is engaged in developing Intellectual Property that can be patented and implemented within our projects and beyond.

The Health and Wellness Division is focused on the acquisition of exclusive patents and IP through licensing agreements. The Company acquired exclusive rights to key patents and IP of Apollon Formularies plc., a UK-based international pharmaceutical company whose formulations and patents specialize in developing cancer treatments from natural biologics, including cannabinoids and functional mushrooms. More recently, the Company has signed a Letter of Intent with B-Organic R&D Corp. relating to the use of their Bioactive Lipid Agents (“BLA”) technology with cannabinoids, terpenes, flavonoids and mushroom extracts. BLA enhances the solubility and bioavailability of various “poorly soluble pharma ingredients”.

These strategic alliances form the basis for the commercialization of promising independently pre-clinically tested formulations, underscoring our commitment to cutting-edge innovation in the commercial biopharma sector.

https://www.globalhempgroup.com/apr924-ghg-provides-mcto-update

Apollon shares were flat at 0.11 pence each on Tuesday afternoon on the AQSE in London. They are down 70% from 0.37 pence each about a year ago on February 14, 2023.

https://www.lse.co.uk/news/apollon-formularies-hails-cancer-killing-results-published-in-journal-4scbjfczedcsnfj.html